Attendee search 

Early stage Biotech investment (VC)

医疗基金

· About Us
Chairman，Mr. Rongguang WU is also the founder of Hongxing Erke , which is one of the most famous sports brands in China. We focus on investing in innovative biotech companies and healthcare funds worldwide. We have an expert team and also seek license-in opportunity of innovative drugs to develop and commercialize in China.

· Investment Cases

Previously, we've invested over 100 million dollars, more than 10 projects worldwide, including VIR Biotechnology, Beijing Genomics institution, GMAX Bio and two Top 10 biomedical funds in America, etc..

· Investment Preference

We don’t have clear limits on the investment scale and the proportion of shares, usually $5 million to $20 million of a single investment. Companies in initial stage to growth stage are all in our consideration. We can lead, co-lead, or join a round that others are leading.

Website：www.hongxingerke.com

Founded in 2007, T&W Group specializes in developing, manufacturing and supplying fine chemicals in Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals. We also have R&D center focusing on CDMO projects for our customer.

Innovative biologics for cancer and other patients' unmet needs

Leading Investment and security company in China

天士力

The North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based, business service provider representing the City of Shenzhen, China´s first Special Economic Zone. Directly sponsored by the Shenzhen Municipal Government and Invest Shenzhen, NAROS offers guidance and consultation to North American companies wishing to enter the Chinese market by means of direct investment within in the City of Shenzhen, as well as to Shenzhen-based companies looking to enter the North American market.

Liquid biopsy blood test for early detection of cancers

We have a very unique T-cell engager Bi-specific antibody platform.

Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.

We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.

We are looking for China partners to codevelop the Bi-specific antibodies.

We are also raising the capital to set up the CHina subsidiary.

You can add my wechat: elite8800